Answer
Concomitant Triumeq and cladribine use is not recommended because lamivudine in Triumeq inhibits intracellular cladribine phosphorylation in vitro, potentially reducing cladribine efficacy; although the interaction has not been studied, some clinical findings support a possible interaction.
Sources for this answer
- Triumeq 50 mg/600 mg/300 mg film-coated tabletsViiV Healthcare UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 33Document updated
Sources checked